Key Drivers
- High gross margin
- Large cash buffer
- Persistent operating losses
AIAI Summary
Tarsus has shifted from a binary clinical bet to a commercial-growth story where XDEMVY's rapid top-line acceleration and ~93% product gross margin make unit economics attractive, but the investment now hinges on management's ability to convert that into corporate profit by materially reducing gross-to-net deductions and demonstrating SG&A leverage. Monitor weekly RX trends, DTC ROI, and quarter-over-quarter gross-to-net improvement—failure to compress rebates or curb opex will likely turn the high multiple into downside.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High gross margin
- •Large cash buffer
- •Persistent operating losses
TARS combines very high gross margins and strong liquidity with low leverage, but persistent operating losses, heavy OPEX/SG&A, negative FCF and a large accumulated deficit mean the current valuation assumes improvement not yet realized.
Price Behavior
Key Price Behavior Insights:
- •Downward bias
- •Potential oversold
- •Resistance cluster
TARS is in a modest downtrend over the last month, losing momentum after the early‑March $77.43 high and recently plunging to $64.51, which could be a short‑term oversold bounce candidate but leaves resistance at $73–$77 intact.
Sharp drop from $74.49 (2026-03-09) to $64.51 (2026-03-20) indicating elevated short-term volatility
Sentiment & News
Key News Insights:
- •Rapid revenue growth
- •Profitability timeline
- •Divergent ownership
Tarsus is showing rapid Xdemvy-driven top-line growth (FY2025 revenue +150%, 2026 guidance $670–700M) and a clear path to 2027 profitability amid active investor outreach and mixed institutional buying/selling.
Strong product momentum and clear guidance should support valuation re-rating if execution stays on track, though mixed institutional moves add short-term sentiment uncertainty
Similar Companies in Healthcare
Other companies in the same sector with AI ratings